A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Min Zhu; Huixue Wang; Jiyong Liu; Hailong He; Xuguo Hua; Qianjun He; Lingxia Zhang; Xiaojian Ye; Jianlin Shi

doi:10.1016/j.biomaterials.2010.11.025

A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Min Zhu, Huixue Wang, Jiyong Liu, Hailong He, Xuguo Hua, Qianjun He, Lingxia Zhang, Xiaojian Ye, Jianlin Shi^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

A composite scaffold drug delivery system (CS-DDS) for osteoarticular tuberculosis therapy has been prepared by loading bi-component drugs into a mesoporous silica nanoparticles (MSNs)-coated porous β-TCP scaffold, which was followed by an additional bioactive glass coating. Such a CS-DDS showed high performances in the local and extremely sustained delivery of the bi-component antitubercular drugs and excellent biocompatibility. N₂ sorption isotherms indicated greatly increased surface area of the composites compared to pure β-TCP scaffold, and the mesopores were around 2.6 nm which were large enough to encapsulate drugs such as isoniazide and rifampicin. The in vitro and in vivo release tests demonstrated extra sustained co-release profiles of rifampicin and isoniazide from such a CS-DDS, and both drug concentrations kept higher than their effective values to kill mycobacterium tuberculosis for as long as 42 days. The hepatic and renal function tests indicated that the CS-DDS had neglectable long-term lesions to liver and kidney.

Original language	English
Pages (from-to)	1986-1995
Number of pages	10
Journal	Biomaterials
Volume	32
Issue number	7
DOIs	https://doi.org/10.1016/j.biomaterials.2010.11.025
State	Published - Mar 2011
Externally published	Yes

Keywords

Antitubercular drugs
Composite drug delivery system
Controlled release
Mesoporous silica nanospheres
β-TCP scaffolds

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biomaterials.2010.11.025

Cite this

@article{e9137fab975343d3a375a1ae2328defd,

title = "A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy",

abstract = "A composite scaffold drug delivery system (CS-DDS) for osteoarticular tuberculosis therapy has been prepared by loading bi-component drugs into a mesoporous silica nanoparticles (MSNs)-coated porous β-TCP scaffold, which was followed by an additional bioactive glass coating. Such a CS-DDS showed high performances in the local and extremely sustained delivery of the bi-component antitubercular drugs and excellent biocompatibility. N2 sorption isotherms indicated greatly increased surface area of the composites compared to pure β-TCP scaffold, and the mesopores were around 2.6 nm which were large enough to encapsulate drugs such as isoniazide and rifampicin. The in vitro and in vivo release tests demonstrated extra sustained co-release profiles of rifampicin and isoniazide from such a CS-DDS, and both drug concentrations kept higher than their effective values to kill mycobacterium tuberculosis for as long as 42 days. The hepatic and renal function tests indicated that the CS-DDS had neglectable long-term lesions to liver and kidney.",

keywords = "Antitubercular drugs, Composite drug delivery system, Controlled release, Mesoporous silica nanospheres, β-TCP scaffolds",

author = "Min Zhu and Huixue Wang and Jiyong Liu and Hailong He and Xuguo Hua and Qianjun He and Lingxia Zhang and Xiaojian Ye and Jianlin Shi",

year = "2011",

month = mar,

doi = "10.1016/j.biomaterials.2010.11.025",

language = "英语",

volume = "32",

pages = "1986--1995",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

AU - Zhu, Min

AU - Wang, Huixue

AU - Liu, Jiyong

AU - He, Hailong

AU - Hua, Xuguo

AU - He, Qianjun

AU - Zhang, Lingxia

AU - Ye, Xiaojian

AU - Shi, Jianlin

PY - 2011/3

Y1 - 2011/3

N2 - A composite scaffold drug delivery system (CS-DDS) for osteoarticular tuberculosis therapy has been prepared by loading bi-component drugs into a mesoporous silica nanoparticles (MSNs)-coated porous β-TCP scaffold, which was followed by an additional bioactive glass coating. Such a CS-DDS showed high performances in the local and extremely sustained delivery of the bi-component antitubercular drugs and excellent biocompatibility. N2 sorption isotherms indicated greatly increased surface area of the composites compared to pure β-TCP scaffold, and the mesopores were around 2.6 nm which were large enough to encapsulate drugs such as isoniazide and rifampicin. The in vitro and in vivo release tests demonstrated extra sustained co-release profiles of rifampicin and isoniazide from such a CS-DDS, and both drug concentrations kept higher than their effective values to kill mycobacterium tuberculosis for as long as 42 days. The hepatic and renal function tests indicated that the CS-DDS had neglectable long-term lesions to liver and kidney.

AB - A composite scaffold drug delivery system (CS-DDS) for osteoarticular tuberculosis therapy has been prepared by loading bi-component drugs into a mesoporous silica nanoparticles (MSNs)-coated porous β-TCP scaffold, which was followed by an additional bioactive glass coating. Such a CS-DDS showed high performances in the local and extremely sustained delivery of the bi-component antitubercular drugs and excellent biocompatibility. N2 sorption isotherms indicated greatly increased surface area of the composites compared to pure β-TCP scaffold, and the mesopores were around 2.6 nm which were large enough to encapsulate drugs such as isoniazide and rifampicin. The in vitro and in vivo release tests demonstrated extra sustained co-release profiles of rifampicin and isoniazide from such a CS-DDS, and both drug concentrations kept higher than their effective values to kill mycobacterium tuberculosis for as long as 42 days. The hepatic and renal function tests indicated that the CS-DDS had neglectable long-term lesions to liver and kidney.

KW - Antitubercular drugs

KW - Composite drug delivery system

KW - Controlled release

KW - Mesoporous silica nanospheres

KW - β-TCP scaffolds

UR - https://www.scopus.com/pages/publications/78650986679

U2 - 10.1016/j.biomaterials.2010.11.025

DO - 10.1016/j.biomaterials.2010.11.025

M3 - 文章

C2 - 21163519

AN - SCOPUS:78650986679

SN - 0142-9612

VL - 32

SP - 1986

EP - 1995

JO - Biomaterials

JF - Biomaterials

IS - 7

ER -

A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this